{"name":"COMPASS Pathways plc","slug":"compass","ticker":"CMPS","exchange":"NASDAQ","domain":"compasspathways.com","description":"COMPASS Pathways plc (CMPS) is a biotech company focused on developing psychedelic medicines for mental health disorders. The company's lead product is COMP360, a psilocybin-based treatment for treatment-resistant depression. COMPASS Pathways has a strong pipeline of psychedelic-based therapies and has established partnerships with leading research institutions. As a leader in the psychedelic medicine space, COMPASS Pathways is well-positioned to capitalize on the growing demand for innovative mental health treatments.","hq":"London, United Kingdom","founded":2016,"employees":"~350","ceo":"Kabir Nath","sector":"Biotech — Psychedelic Medicine","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"1.4B","metrics":{"revenue":2000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":118436000,"netIncome":-287862000,"cash":149608000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-09","type":"regulatory","headline":"COMPASS Pathways Announces FDA Breakthrough Therapy Designation for COMP360","summary":"COMPASS Pathways announced that the FDA has granted Breakthrough Therapy designation for COMP360, its psilocybin-based treatment for treatment-resistant depression.","drugName":"COMP360","sentiment":"positive"},{"date":"2022-11-15","type":"earnings","headline":"COMPASS Pathways Reports Third Quarter 2022 Financial Results","summary":"COMPASS Pathways reported its third quarter 2022 financial results, with revenue of $13.4 million and a net loss of $34.6 million.","drugName":"","sentiment":"neutral"},{"date":"2022-09-01","type":"deal","headline":"COMPASS Pathways Announces Collaboration with the University of California, San Francisco","summary":"COMPASS Pathways announced a collaboration with the University of California, San Francisco to study the use of psilocybin for the treatment of depression.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-24","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-24","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE9kQ19XWFd0SWdzUlN5MFJJZWZEV0dWNmd0ckhzNW56Xzd4dkhqNTJ1NjVsLURYa1ZWaVpGZ2FTYVIzTndDenVKelMwZ2xVVUM1ajVSdTRIS0FlSU5RZnd4aUFzN1RyMXRNWWo3ck53?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Compass Pathways Plc (CMPS) - Stock Titan","headline":"If You Invested $1,000 in Compass Pathways Plc (CMPS)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPUXRBYVdMb29hZXVveTl1MmFPU0VEaXdtR2t2T2hMdldOU2hxSWdEY0RiS05MajhTRGhUVHhNUzU4WC1leGtIY2VkVlF4OFdDZ2RyR1dtNFdIdHBlSG5KUm9aTWdxRGV0LUpsOVJmY1ZOdnpBWFN0U0NfcGFCMlV2ZE5BaExCbzM4M1ZBQ3BiQUNrWGVsbWhMYzF0NGFsdFkzWEg3cw?oc=5","date":"2026-03-09","type":"regulatory","source":"investingnews.com","summary":"CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions - investingnews.com","headline":"CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQRDFIR0ltRG1qd0h5Q2dFcVhaOE92TXVXNXRwNzhUU0lvRjBwbWl4MWdvNEw1aUpwRmJrM3IzT0VDV2thUDE2enhPX0JFTGdKMHkyQ2hnWkh3WHB0dEx6STFpbVZLa09SdVF6QkJSRU1kd29tcXBGNGNpVWgxdjV5UmpRTmVZMjdPT1VsejdkY3pvWW9QeUcydWs4UmRnUjNYSTVQRg?oc=5","date":"2026-02-24","type":"pipeline","source":"investingnews.com","summary":"Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity - investingnews.com","headline":"Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxOMG5lX1BqZWxTcW9NcDZPRDBsdkNLOTlWUEhsdy1aMUFWbE9QaHBXTGZEOS1fellnYW44Sk4zUEdKTkNxZUdJaDh3OEpkSlREQTRjZVZNVDhtQVBfczZxTmsyME1pc1h1VzNtUVVTcnBVcXVoOTdCNVJMLUI0M2lhMWNfaHA4TGRucGZ4WXdrOXI0UW9DWjZzRzZB?oc=5","date":"2026-02-20","type":"trial","source":"Finviz","summary":"Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise - Finviz","headline":"Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise","sentiment":"neutral"},{"date":"2026-02-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOY09Bbk9qV3Z5U3VKNUo1SWpySFRFNkdEUWdfWU0tS20zOW8zMkFfeTJhaWdfS1lUU2JBd3hOajN4clRvZ0g4SnBJU0FYQkRvM1Q1a0tBSXByUjVWT2dPWWcxOGl3Um5VLXZ0UWNqMzdxZFJNdVZCdDJsTzQxSHNSb3NRcFVMd3BWQWx4czlTeE9oY2xkTEhjUlh6dkgzckxUalZMZXlRRXB1LXBRUktobkJwOGRsQzZWcmRwX2VFNkZ1S2tZMnc?oc=5","date":"2026-02-18","type":"pipeline","source":"Finviz","summary":"Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates - Finviz","headline":"Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-18","type":"trial","source":"simplywall.st","summary":"Why COMPASS Pathways (CMPS) Is Up 21.3% After Phase 3 Psilocybin Win And $150M Equity Raise - simplywall.st","headline":"Why COMPASS Pathways (CMPS) Is Up 21.3% After Phase 3 Psilocybin Win And $150M Equity Raise","sentiment":"neutral"},{"date":"2026-02-17","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQQlA0Z2lyT2JuOE9pYUJpN2wxOEpuTW41eEtfQnhteVBLZWptZVVZUHVBbFl6TG5FX2FVcEozNU9PR2hJU0p4a2g5QkZqM3ZOekZ2aHJsZ0VscjFUY2hqY0diQTl1TEJEeU5UNnNjcHFQS0VNVVNMY0dPQ1dEaFBlVmN2Vm9Fa2cyV2hsVmhxaGlkVFZkNTdOQVJwLW9CZThYVzJ6Y0hVbGtmUUc4TEdnZ1hZQW9aejBBdER2OHdNVl9TZjJsTGgtR1BxRUpqU013?oc=5","date":"2026-02-16","type":"trial","source":"Business Wire","summary":"Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials - Business Wire","headline":"Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNRXFQSzVHZ0tjdGRNNXExQjdVRWJIOWswNUNPZWFvMHM3X3pSX01PM0VEVENBSkVSOC10aTlNc29oejZqcGZkcE1QbWtWeXZxYk1DZmVCSXRya1pjRnBMbVlvNDJobzFzVTdJMDV3Wm5kMFFFakRUZm9UQnAtcERVWWlmOF82RE11T2JQYWhzV1E1YkE?oc=5","date":"2026-02-05","type":"deal","source":"The Motley Fool","summary":"5 Psychedelic Stocks to Buy Now - The Motley Fool","headline":"5 Psychedelic Stocks to Buy Now","sentiment":"neutral"},{"date":"2026-01-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQREpncDNEOEo2NF9BSTNvckRfd2JlZ3ZQSDNSMmxWTmhiTnFQR0EzRl9sM2t2MGd5T2EyYktadzFpYnNwRmVhM0lNVzl2RVNGZ2xlZlJQLXRyZDZyYU1HWU1ESlJ5Y2wzdElrWkFfRm1EZ2JDY0dPczVyODBTSXdkMDYwVDBLUzl5cU9SQnVCY3FXOFBieFo0?oc=5","date":"2025-12-27","type":"pipeline","source":"Finviz","summary":"Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution - Finviz","headline":"Why COMPASS Pathways plc (CMPS) Draws Both Optimism and Caution","sentiment":"neutral"},{"date":"2025-11-04","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Johnson & Johnson","Pfizer","Eli Lilly and Company"],"therapeuticFocus":["Mental Health Disorders","Depression"],"financials":{"source":"sec_edgar","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":118436000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-287862000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":149608000,"cashHistory":[],"totalAssets":210349000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}